MAIA Biotechnology, Inc. (@MAIABiotech) / X

MAIA Biotechnology, Inc.

396 posts

MAIA Biotechnology, Inc.

@MAIABiotech

MAIA Biotech is a targeted therapy, immuno-oncology company focused on the development and commercialization of first-in-class drugs. $MAIA

Chicago, IL USA

Joined June 2020

MAIA Biotechnology, Inc.
@MAIABiotech
Jun 6, 2024
Today, MAIA announced key achievements year-to-date, including recent #clinical progress for lead candidate THIO, a potential first-in-class cancer telomere targeting agent in clinical development to evaluate its activity in #NSCLC. Read: bit.ly/4bNqiy7 $MAIA
1.3K
MAIA Biotechnology, Inc.
@MAIABiotech
Jun 24, 2024
MAIA and @CromosPharma are part of an innovative collaboration to advance cancer treatment focused on THIO, a groundbreaking telomere-targeting agent for #NSCLC. Read the news here: bit.ly/3XAFUkg $MAIA #ASCO2024
4K
MAIA Biotechnology, Inc.
@MAIABiotech
May 31, 2024
#ASCO24 has begun! The MAIA team is having a productive first day and our CEO, Vlad Vitoc, is holding meetings with KOLs. Make sure to stop by our poster presentation in the #NSCLC Metastatic session on Monday, 6/3, 1:30 - 4:30pm CT in Hall A at Board 465 - Abstract 8601. $MAIA
2.2K
MAIA Biotechnology, Inc.
@MAIABiotech
Jun 3, 2024
Don't miss our poster presentation today at 1:30pm CT at #ASCO24! Board 465 | Abstract 8601 We're looking forward to sharing the latest data from our Phase 2 THIO-101 clinical trial for patients with advanced #NSCLC. See you there! Details: bit.ly/4dL9ngY $MAIA
2.2K
MAIA Biotechnology, Inc.
@MAIABiotech
Jul 28, 2024
#OnThisDay two years ago, MAIA listed on the @NYSE. This milestone reflects our dedication to #clinicalresearch for our lead candidate in development, THIO, a telomere targeting agent that has shown exceptional efficacy on patients in NSCLC. $MAIA #NYSE #Biotech #Innovation
6.8K
MAIA Biotechnology, Inc.
@MAIABiotech
Jun 3, 2024
Today at 1:30pm CT, MAIA’s poster presentation revealing new efficacy data from Phase 2 THIO-101 trial in #NSCLC will be presented at #ASCO24. It is also available on our website here: bit.ly/4bI0wuC $MAIA
2.5K
MAIA Biotechnology, Inc.
@MAIABiotech
Jun 10, 2024
Our most recent #clinical data points to THIO’s unprecedented DCR of 85%, ORR of 38%, and post-therapy patient benefits. Third-line treatment with THIO has far outperformed reported standard-of-care data in #NSCLC. Read our latest news: bit.ly/4bNqiy7 $MAIA #Oncology
5.3K
MAIA Biotechnology, Inc.
@MAIABiotech
Jun 25, 2024
Pleased to share that Dr. Jankowski, the presenting author of MAIA’s poster at #ASCO24 and key investigator in our Phase 2 #clinicaltrial, was selected as one of the very few authors to provide a video update. Watch his discussion via @ASCOPost: bit.ly/3RExJja $MAIA
ascopost.com
Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent
859
MAIA Biotechnology, Inc.
@MAIABiotech
Jun 5, 2024
MAIA announced new efficacy data from our Phase 2 THIO-101 #clinicaltrial evaluating THIO in patients with #NSCLC greatly surpassing the standard-of-care with ORR of 38% and DCR of 85% in third-line treatment. Dive into the press release: bit.ly/4aMMFlZ $MAIA #ASCO24
1.2K
MAIA Biotechnology, Inc.
@MAIABiotech
Jun 4, 2024
MAIA Biotechnology Reveals New #Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer. Read the press release here: bit.ly/4aMMFlZ $MAIA #NSCLC #Oncology #ASCO24
2.4K
MAIA Biotechnology, Inc.
@MAIABiotech
Jun 7, 2024
MAIA’s newest data shows THIO’s strong outperformance against standard-of-care treatments in #NSCLC. THIO-101 clinical data showed: ORR of 38% DCR of 85% Dive into the press release: bit.ly/4bNqiy7 $MAIA #ClinicalResearch #CancerResearch
833
MAIA Biotechnology, Inc.
@MAIABiotech
Jun 5, 2024
Today at 11:30am PT, Dr. Vitoc is presenting at #BIO2024 to highlight findings from MAIA’s Phase 2 THIO-101 clinical trial evaluating THIO, our telomere-targeting agent, in #NSCLC patients. Hope to see you there! $MAIA
1.2K
MAIA Biotechnology, Inc.
@MAIABiotech
May 29, 2024
MAIA looks forward to revealing the newest efficacy results from THIO-101 and discussing our pioneering telomere targeting science underlying THIO. Our poster will be presented on 6/3 at 1:30pm CT. More information here: bit.ly/4dL9ngY
1.1K
MAIA Biotechnology, Inc.
@MAIABiotech
Jul 25, 2024
Ongoing benefits of THIO in longer-term patients are particularly notable, signifying THIO’s potential as a durable and efficacious treatment for advanced #NSCLC patients. Read the latest clinical updates from our Phase 2 #clinicaltrial of THIO-101: bit.ly/4cP1AOD $MAIA
1.2K